Regulation of Id1 expression by Src: Implications for targeting of the bone morphogenetic protein pathway in cancer

Oliver Gautschi, Clifford G. Tepper, Phillip R. Purnell, Yoshihiro Izumiya, Christopher P. Evans, Tim P. Green, Pierre Y. Desprez, Primo N. Lara, David R. Gandara, Philip C. Mack, Hsing Jien Kung

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Deregulated activation of the Src tyrosine kinase and heightened Id1 expression are independent mediators of aggressive tumor biology. The present report implicates Src signaling as a critical regulator of Id1 gene expression. Microarray analyses showed that Id family genes were among the most highly down-regulated by incubation of A549 lung carcinoma cells with the small-molecule Src inhibitor AZD0530. Id1 transcript and protein levels were potently reduced in a dose-dependent manner concomitantly with the reduction of activated Src levels. These effects were conserved across a panel of lung, breast, prostate, and colon cancer cell lines and confirmed by the ability of PP2, Src siRNA, and Src-blocking peptides to suppress Id1 expression. PP2, AZD0530, and dominant-negative Src abrogated Id1 promoter activity, which was induced by constitutively active Src. The Src-responsive region of the Id1 promoter was mapped to a region 1,199 to 1,360 bps upstream of the translation start site and contained a Smad-binding element. Src was also required for bone morphogenetic protein-2 (BMP-2)-induced Id1 expression and promoter activity, was moderately activated by BMP-2, and complexed with Smad1/5. Conversely, Src inhibitors blocked Smad1/5 nuclear translocation and binding to the Src-responsive region of the Id1 promoter. Consistent with a role for Src and Id1 in cancer cell invasion, Src inhibitors and Id1 siRNAdecr eased cancer cell invasion, which was increased by Id1 overexpression. Taken together, these results reveal that Src positively interacts with the BMP-Smad-Id pathway and provide new ways for targeted inhibition of Id1.

Original languageEnglish
Pages (from-to)2250-2258
Number of pages9
JournalCancer Research
Volume68
Issue number7
DOIs
Publication statusPublished - Apr 1 2008
Externally publishedYes

Fingerprint

Bone Morphogenetic Proteins
Bone Morphogenetic Protein 2
Src peptide
Genetic Promoter Regions
Neoplasms
src-Family Kinases
Small Cell Lung Carcinoma
Regulator Genes
Microarray Analysis
Colonic Neoplasms
Small Interfering RNA
Lung Neoplasms
Prostatic Neoplasms
Breast Neoplasms
Gene Expression
Cell Line
Genes
Proteins
saracatinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Regulation of Id1 expression by Src : Implications for targeting of the bone morphogenetic protein pathway in cancer. / Gautschi, Oliver; Tepper, Clifford G.; Purnell, Phillip R.; Izumiya, Yoshihiro; Evans, Christopher P.; Green, Tim P.; Desprez, Pierre Y.; Lara, Primo N.; Gandara, David R.; Mack, Philip C.; Kung, Hsing Jien.

In: Cancer Research, Vol. 68, No. 7, 01.04.2008, p. 2250-2258.

Research output: Contribution to journalArticle

Gautschi, O, Tepper, CG, Purnell, PR, Izumiya, Y, Evans, CP, Green, TP, Desprez, PY, Lara, PN, Gandara, DR, Mack, PC & Kung, HJ 2008, 'Regulation of Id1 expression by Src: Implications for targeting of the bone morphogenetic protein pathway in cancer', Cancer Research, vol. 68, no. 7, pp. 2250-2258. https://doi.org/10.1158/0008-5472.CAN-07-6403
Gautschi, Oliver ; Tepper, Clifford G. ; Purnell, Phillip R. ; Izumiya, Yoshihiro ; Evans, Christopher P. ; Green, Tim P. ; Desprez, Pierre Y. ; Lara, Primo N. ; Gandara, David R. ; Mack, Philip C. ; Kung, Hsing Jien. / Regulation of Id1 expression by Src : Implications for targeting of the bone morphogenetic protein pathway in cancer. In: Cancer Research. 2008 ; Vol. 68, No. 7. pp. 2250-2258.
@article{8d35af2cfd2e4fba9db74c07e1fda8f1,
title = "Regulation of Id1 expression by Src: Implications for targeting of the bone morphogenetic protein pathway in cancer",
abstract = "Deregulated activation of the Src tyrosine kinase and heightened Id1 expression are independent mediators of aggressive tumor biology. The present report implicates Src signaling as a critical regulator of Id1 gene expression. Microarray analyses showed that Id family genes were among the most highly down-regulated by incubation of A549 lung carcinoma cells with the small-molecule Src inhibitor AZD0530. Id1 transcript and protein levels were potently reduced in a dose-dependent manner concomitantly with the reduction of activated Src levels. These effects were conserved across a panel of lung, breast, prostate, and colon cancer cell lines and confirmed by the ability of PP2, Src siRNA, and Src-blocking peptides to suppress Id1 expression. PP2, AZD0530, and dominant-negative Src abrogated Id1 promoter activity, which was induced by constitutively active Src. The Src-responsive region of the Id1 promoter was mapped to a region 1,199 to 1,360 bps upstream of the translation start site and contained a Smad-binding element. Src was also required for bone morphogenetic protein-2 (BMP-2)-induced Id1 expression and promoter activity, was moderately activated by BMP-2, and complexed with Smad1/5. Conversely, Src inhibitors blocked Smad1/5 nuclear translocation and binding to the Src-responsive region of the Id1 promoter. Consistent with a role for Src and Id1 in cancer cell invasion, Src inhibitors and Id1 siRNAdecr eased cancer cell invasion, which was increased by Id1 overexpression. Taken together, these results reveal that Src positively interacts with the BMP-Smad-Id pathway and provide new ways for targeted inhibition of Id1.",
author = "Oliver Gautschi and Tepper, {Clifford G.} and Purnell, {Phillip R.} and Yoshihiro Izumiya and Evans, {Christopher P.} and Green, {Tim P.} and Desprez, {Pierre Y.} and Lara, {Primo N.} and Gandara, {David R.} and Mack, {Philip C.} and Kung, {Hsing Jien}",
year = "2008",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-07-6403",
language = "English",
volume = "68",
pages = "2250--2258",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Regulation of Id1 expression by Src

T2 - Implications for targeting of the bone morphogenetic protein pathway in cancer

AU - Gautschi, Oliver

AU - Tepper, Clifford G.

AU - Purnell, Phillip R.

AU - Izumiya, Yoshihiro

AU - Evans, Christopher P.

AU - Green, Tim P.

AU - Desprez, Pierre Y.

AU - Lara, Primo N.

AU - Gandara, David R.

AU - Mack, Philip C.

AU - Kung, Hsing Jien

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Deregulated activation of the Src tyrosine kinase and heightened Id1 expression are independent mediators of aggressive tumor biology. The present report implicates Src signaling as a critical regulator of Id1 gene expression. Microarray analyses showed that Id family genes were among the most highly down-regulated by incubation of A549 lung carcinoma cells with the small-molecule Src inhibitor AZD0530. Id1 transcript and protein levels were potently reduced in a dose-dependent manner concomitantly with the reduction of activated Src levels. These effects were conserved across a panel of lung, breast, prostate, and colon cancer cell lines and confirmed by the ability of PP2, Src siRNA, and Src-blocking peptides to suppress Id1 expression. PP2, AZD0530, and dominant-negative Src abrogated Id1 promoter activity, which was induced by constitutively active Src. The Src-responsive region of the Id1 promoter was mapped to a region 1,199 to 1,360 bps upstream of the translation start site and contained a Smad-binding element. Src was also required for bone morphogenetic protein-2 (BMP-2)-induced Id1 expression and promoter activity, was moderately activated by BMP-2, and complexed with Smad1/5. Conversely, Src inhibitors blocked Smad1/5 nuclear translocation and binding to the Src-responsive region of the Id1 promoter. Consistent with a role for Src and Id1 in cancer cell invasion, Src inhibitors and Id1 siRNAdecr eased cancer cell invasion, which was increased by Id1 overexpression. Taken together, these results reveal that Src positively interacts with the BMP-Smad-Id pathway and provide new ways for targeted inhibition of Id1.

AB - Deregulated activation of the Src tyrosine kinase and heightened Id1 expression are independent mediators of aggressive tumor biology. The present report implicates Src signaling as a critical regulator of Id1 gene expression. Microarray analyses showed that Id family genes were among the most highly down-regulated by incubation of A549 lung carcinoma cells with the small-molecule Src inhibitor AZD0530. Id1 transcript and protein levels were potently reduced in a dose-dependent manner concomitantly with the reduction of activated Src levels. These effects were conserved across a panel of lung, breast, prostate, and colon cancer cell lines and confirmed by the ability of PP2, Src siRNA, and Src-blocking peptides to suppress Id1 expression. PP2, AZD0530, and dominant-negative Src abrogated Id1 promoter activity, which was induced by constitutively active Src. The Src-responsive region of the Id1 promoter was mapped to a region 1,199 to 1,360 bps upstream of the translation start site and contained a Smad-binding element. Src was also required for bone morphogenetic protein-2 (BMP-2)-induced Id1 expression and promoter activity, was moderately activated by BMP-2, and complexed with Smad1/5. Conversely, Src inhibitors blocked Smad1/5 nuclear translocation and binding to the Src-responsive region of the Id1 promoter. Consistent with a role for Src and Id1 in cancer cell invasion, Src inhibitors and Id1 siRNAdecr eased cancer cell invasion, which was increased by Id1 overexpression. Taken together, these results reveal that Src positively interacts with the BMP-Smad-Id pathway and provide new ways for targeted inhibition of Id1.

UR - http://www.scopus.com/inward/record.url?scp=42049092982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049092982&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-6403

DO - 10.1158/0008-5472.CAN-07-6403

M3 - Article

C2 - 18381431

AN - SCOPUS:42049092982

VL - 68

SP - 2250

EP - 2258

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -